Accelerating Innovation at Leica Biosystems

Outstanding First 18 Months at Cytiva KEY PRIORITIES & PROGRESS SINCE ACQUISITION cytiva RECENT FINANCIAL RESULTS Brand Establishment 32K Stand-up Systems & Processes PRODUCTS & SIGNAGE UPDATED >200 TSAS TRANSITIONED Embracing DBS +>2X OUTPUT OF U.S. SUT PRODUCTS >3PTS BRAND POWER & PREMIUM VS PEERS (KANTAR) AT ACQ. 2021E Revenue ~$3B -$6B >1,500 ASSOCIATES HIRED Core growth +6-7%* +>35% OMX >500bps ROIC IMPROVEMENT IN +HSD * Anticipated long-term growth rate 2X PROJECT OTD WITHIN FIRST YEAR Exceeding our initial expectations on all fronts DANAHER

View entire presentation